Category - Feature

Feature

Qualigen advancing platform technologies in therapeutics and diagnostics

Backed by a commercial diagnostics business, Qualigen Therapeutics (NASDAQ:QLGN) has broadened its focus to developing platform therapeutics for cancer with potential orphan drug designation.

May 10, 2022

Feature

Talking mental health with Chris Wang of Shimmer

As co-founder and CEO of Shimmer, a provider of a science-backed process to reduce stress and anxiety, Chris Wang took an early interest in social impact consulting at her first job with Bain & Co. But a close family...

May 3, 2022

Feature

Claritas Pharmaceuticals transforming nitric oxide therapy

Claritas Pharmaceuticals (TSXV:CLAS; OTC:CLAZF) is developing R-107, a liquid drug candidate that may hold the key to transforming nitric oxide therapy from its current gaseous inhalation method of delivery to...

April 26, 2022

Feature

In conversation with Dr. Murat Kalayoglu of Cartesian

As president and CEO of closely-held Cartesian Therapeutics, Murat Kalayoglu, M.D., Ph.D., has made a smooth transition over the years from a board-certified ophthalmologist to a healthcare IT entrepreneur to a medical...

April 12, 2022

Feature

Cocrystal Pharma advancing programs in high-value antiviral drug targets

With a drug discovery technology platform developed by several Nobel Prize laureates, Cocrystal Pharma (NASDAQ:COCP) is advancing broad spectrum antivirals in three programs: coronaviruses and variants, pandemic and...

April 5, 2022

Feature

180 Life Sciences focused on one of largest drivers of disease: inflammation

180 Life Sciences (NASDAQ:ATNF) has three families of novel biologic drugs in synchronized stages of development, addressing separate areas of inflammation, fibrosis and pain, for which there are no effective therapies.

March 29, 2022

Feature

First Wave developing targeted, non-systemic therapies for GI diseases

First Wave BioPharma (NASDAQ:FWBI) is advancing multiple clinical-stage programs built around its two proprietary technologies: niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and a...

March 22, 2022

Feature

Transforming biologic drug discovery with Sean McClain of Absci

As CEO and founder of Absci (NASDAQ:ABSI), a drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, Sean McClain has come a long way in the...

March 15, 2022

Feature

Ampio to seek FDA agreement on modified intent-to-treat BLA in severe OAK

Ampio Pharmaceuticals (NYSE American:AMPE), citing a significant impact from COVID-19 on its second confirmatory Phase 3 trial of Ampion for the treatment of severe osteoarthritis of the knee (OAK), hopes to meet with...

March 8, 2022

Feature

Precigen advancing pipeline of gene and cell therapies in I-O, autoimmune, infectious disorders

Precigen (NASDAQ:PGEN) is advancing a pipeline of next generation gene and cell therapies using precision technology in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.

March 1, 2022

Category - Feature

Qualigen advancing platform technologies in therapeutics and diagnostics

Talking mental health with Chris Wang of Shimmer

Claritas Pharmaceuticals transforming nitric oxide therapy

In conversation with Dr. Murat Kalayoglu of Cartesian

Cocrystal Pharma advancing programs in high-value antiviral drug targets

180 Life Sciences focused on one of largest drivers of disease: inflammation

First Wave developing targeted, non-systemic therapies for GI diseases

Transforming biologic drug discovery with Sean McClain of Absci

Ampio to seek FDA agreement on modified intent-to-treat BLA in severe OAK

Precigen advancing pipeline of gene and cell therapies in I-O, autoimmune, infectious disorders

General

More